Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

The Journal of Immunology : Official Journal of the American Association of Immunologists
A M McCallL M Weiner

Abstract

We tested the hypothesis that bispecific Abs (Bsab) with increased binding affinity for tumor Ags augment retargeted antitumor cytotoxicity. We report that an increase in the affinity of Bsab for the HER2/neu Ag correlates with an increase in the ability of the Bsab to promote retargeted cytotoxicity against HER2/neu-positive cell lines. A series of anti-HER2/neu extracellular domain-directed single-chain Fv fragments (scFv), ranging in affinity for HER2/neu from 10(-7) to 10(-11) M, were fused to the phage display-derived NM3E2 human scFV: NM3E2 associates with the extracellular domain of human FcgammaRIII (CD16). The resulting series of Bsab promoted cytotoxicity of SKOV3 human ovarian carcinoma cells overexpressing HER2/neu by human PBMC preparations containing CD16-positive NK cells. The affinity for HER2/neu clearly influenced the ability of the Bsab to promote cytotoxicity of (51)Cr-labeled SKOV3 cells. Lysis was 6.5% with an anti-HER2/neu K(D) = 1.7 x 10(-7) M, 14.5% with K(D) = 5.7 x 10(-9) M, and 21.3% with K(D) = 1.7 x 10(-10) M at 50:1 E:T ratios. These scFv-based Bsab did not cross-link receptors and induce leukocyte calcium mobilization in the absence of tumor cell engagement. Thus, these novel Bsab structures shou...Continue Reading

References

Jan 1, 1991·Methods in Enzymology·J S HustonH Oppermann
Mar 1, 1989·Immunology Today·M W FangerP M Guyre
Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vadhan-RajA N Houghton
Jan 1, 1988·Cancer Investigation·D M Segal, J R Wunderlich
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F H ValoneM Mrozek-Orlowski
Jul 28, 1995·International Journal of Cancer. Journal International Du Cancer·Z ZhuP Carter
Aug 12, 1993·The New England Journal of Medicine·M S KaminskiG M Butchko
Oct 1, 1995·Journal of Hematotherapy·D M KranzE R Wilson
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaL Norton
Mar 1, 1996·Cancer Immunology, Immunotherapy : CII·L M WeinerM W Barth
Mar 1, 1997·Immunology Today·Y M DeoJ G van de Winkel
Mar 1, 1997·The International Journal of Biochemistry & Cell Biology·P J VossebeldA J Verhoeven
May 1, 1995·Immunotechnology : an International Journal of Immunological Engineering·R SchierL M Weiner
Apr 16, 1998·International Journal of Cancer. Journal International Du Cancer·W HelfrichL de Leij
Jul 14, 1998·Immunotechnology : an International Journal of Immunological Engineering·A M McCallL M Weiner

❮ Previous
Next ❯

Citations

Apr 4, 2003·International Journal of Cancer. Journal International Du Cancer·Pauline WimbergerRainer Kimmig
Jun 29, 2004·World Journal of Gastroenterology : WJG·Jing ZhangHua-Zhang Guo
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Oct 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Chan Hyuk KimPeter G Schultz
Jan 11, 2017·MAbs·Ulrich Brinkmann, Roland E Kontermann
Feb 26, 2019·Frontiers in Oncology·Gaurav NayyarMitchell S Cairo
Aug 14, 2002·World Journal of Gastroenterology : WJG·Yong-Zhan NieDai-Ming Fan
Jun 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sergey M KipriyanovMelvyn Little
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Torsten DreierPatrick A Baeuerle
Dec 26, 2002·Journal of Molecular Recognition : JMR·Rebecca L Rich, David G Myszka
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yong TangLouis M Weiner
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Oct 13, 2015·Current Opinion in Hematology·Divaya Bhutani, Lawrence G Lum
Aug 23, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Bushra Husain, Diego Ellerman
Dec 1, 2001·Expert Opinion on Biological Therapy·P J Hudson, C Souriau
Jan 22, 2005·Acta Pharmacologica Sinica·Roland E Kontermann
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Jan 26, 2017·Clinical and Experimental Medicine·Hailing LiuFuling Zhou
Jul 26, 2017·Frontiers in Immunology·Bing-Mae ChenSteve R Roffler
Dec 19, 2009·Protein Engineering, Design & Selection : PEDS·Kelly Davis OrcuttK Dane Wittrup
Jul 10, 2010·Protein Engineering, Design & Selection : PEDS·Steve SchoonoogheJohan Grooten
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claire GermainBruno Robert
Jan 17, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Virginia J YaoRenata Pasqualini
Apr 27, 2021·Expert Opinion on Biological Therapy·Patrick M DillonLawrence G Lum
Apr 28, 2004·Trends in Biotechnology·Peter KuferPatrick A Baeuerle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.